Xu, Kailin

Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial

Xia, J., Li, H., Yan, Z., Zhou, D., Wang, Y., Qi, Y., Cao, J., Li, D., Cheng, H., Sang, W., et al. (2023) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 94

Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc/Max heterodimerization and disturbing its stability

Yao, R., Zhang, M., Zhou, J., Liu, L., Zhang, Y., Gao, J., & Xu, K. (2022) · Cell Communication and Signaling

Multiple Myeloma Research and TreatmentsCancer-related Molecular Pathways

Cited by 32

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting

Xia, J., Li, Z., & Xu, K. (2023) · Journal of Hematology & Oncology

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 13